Background
Over the past 14 years, I have gained multi-disciplinary training in cancer immunology, autoimmunity, immune aging, early life immunity, and computational biology. My current research employs systems immunology approaches to investigate immune remodeling across the human lifespan.
Experience
The Jackson Laboratory for Genomic Medicine - Farmington, CT, USA
- Research Scientist: 2023 – present (Ucar lab)
- Associate Research Scientist: 2019 – 2023 (Banchereau lab, then Verhaak lab)
- Postdoctoral Associate: 2016 – 2019 (Banchereau lab)
Sorbonne University (Pierre & Marie Curie) - Paris, France
Research Highlights
Throughout my career at the Jackson Lab, I have led collaborative studies and developed computational frameworks to analyze genomic datasets, including scRNA-seq, ATAC-seq, and spatial transcriptomics. Key projects include:
-
Pediatric SLE patient classification through single-cell derived genomic signatures — Developed computational pipelines using bulk and scRNA-seq to analyze large-scale datasets and enhance the accuracy of SLE patient classification.
-
NK-like senescent CD8+ T cells that expand with age — Built computational frameworks to profile age-related immune senescence.
-
Longitudinal evaluation of the immune response to routine vaccines in infants — Created computational models for studying immune cell dynamics in two-month-old infants.
-
Immune perturbations in two-month-old infants with severe COVID-19 — Leveraged scRNA-seq, cytokine profiling, and antibody analysis to develop an automated multi-omic framework comparing immune responses across infants, children, and adults.
Early Research
During my predoctoral training (Klatzmann lab; Sorbonne University, Paris, France; 2010–2016), I investigated immune tolerance mechanisms shared between embryos and tumors. Using murine models, I demonstrated that regulatory T cells (Tregs) orchestrate similar immune evasion in both fetuses and tumors. Transcriptomic profiling and flow cytometry of the tumor microenvironment revealed that co-silencing of TGF-β and VEGF led to substantial spontaneous tumor eradication, with synergistic effects from their respective inhibitors. A collaboration with the Aryee lab (Massachusetts General Hospital & Harvard Medical School) validated these findings in human data.